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WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT

Keywords: Colorectal Cancer; Tumor Microenvironment; AlphaSmooth Muscle Actin (aSMA); CD146.

C

olorectal cancer (CRC) is a leading cause of cancerrelated death. Cancer-associated ﬁbroblasts (CAFs)
are histologically prominent and biologically important in
CRC initiation, progression, and metastasis.1 CAFs
contribute to carcinogenesis via secretion of growth factors,
cytokines, pro-angiogenic factors, and extracellular matrix.1
Recent studies using immunophenotyping and single-cell
RNA sequencing (scRNA-seq) have revealed that CAFs
contain heterogeneous subpopulations.2 It is now apparent
that distinct CAF populations have different consequences
on cancer growth. Some CAFs promote while others retard
cancer growth.3 The cellular origins of CAFs, whether promoting or retarding, are poorly understood.1 Regarding the
development and consequences of CAFs on CRC growth,
there remain at least 3 unresolved questions. First, are CAFs
newly generated cells arising through proliferation, or
simply old cells acquiring a new phenotype? Second, if any

Cancer-associated ﬁbroblasts (CAFs) regulate colorectal
cancer (CRC) progression. However, the cellular origin
of CAFs and how speciﬁc CAF lineages contribute to
CRC progression are unknown.
NEW FINDINGS
Colonic pericryptal leptin receptor (LepR)–lineage cells are
a major source of MCAMþ and ACTA2þ CAFs. These
MCAMþ CAFs accelerate CRC progression via nuclear
factor
kB–IL34/CCL8–mediated
tumor-associated
macrophage recruitment.
LIMITATIONS
This study was performed using mouse models and
human tissue samples. Future studies are necessary to
assess the therapeutic efﬁcacy of targeting LEPRlineage MCAMþ CAFs in patients with CRC.
IMPACT
Inhibiting proliferation/differentiation of LEPRþ cells to
MCAMþ CAFs or targeting mature MCAMþ CAFs in
established cancer are novel potential therapeutic
strategies to treat CRC.

of the CAFs emerge through proliferation, what is their
cellular origin? And third, what CAF-derived factors promote cancer progression, and could those be targeted with
novel stromal therapies?
Theoretically, CAFs could arise through at least four
nonmutually exclusive mechanisms: proliferation, activation, transdifferentiation, and recruitment.1 Although
studies using autochthonous mouse models of cancers
have indicated that some CAFs undergo proliferation,4,5
the relative contribution of proliferating and nonproliferating CAFs to the entire pool remains unclear.
Induced by factors such as transforming growth factor
(TGF) b,6 quiescent ﬁbroblasts might undergo phenotypic
conversion into activated CAFs: an old cell, but with a new
mask (ie, activation). Third, several fate-mapping studies
have indicated that nonﬁbroblast lineage cells, such as
epithelial cells, could transdifferentiate into CAFs through
epithelial-to-mesenchymal
transition
(ie,
transdifferentiation).7 Finally, bone marrow transplantation
experiments have indicated that about 20% of ACTA2þ (asmooth muscle actin) CAFs were recruited from the bone

* These authors contributed equally.
Abbreviations used in this paper: ACTA2, a-smooth muscle actin; AOM,
azoxymethane; BrdU, 5-bromodeoxyuridine; CAF, cancer-associated
ﬁbroblast; CMS, consensus molecular subtype; CRC, colorectal cancer;
DSS, dextran sodium sulfate; FACS, ﬂuorescence-activated cell sorting;
Lepr, leptin receptor; MCAM, melanoma cell adhesion molecule; RFP, red
ﬂuorescent protein; scRNA-seq, single-cell RNA-sequencing; TAM, tumor-associated macrophage; TCGA, The Cancer Genome Atlas; TGF-b,
transforming growth factor b.
Most current article
© 2022 by the AGA Institute
0016-5085/$36.00
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BACKGROUND & AIMS: Cancer-associated ﬁbroblasts (CAFs)
play an important role in colorectal cancer (CRC) progression
and predict poor prognosis in CRC patients. However, the
cellular origins of CAFs remain unknown, making it challenging
to therapeutically target these cells. Here, we aimed to identify
the origins and contribution of colorectal CAFs associated with
poor prognosis. METHODS: To elucidate CAF origins, we used
a colitis-associated CRC mouse model in 5 different fatemapping mouse lines with 5-bromodeoxyuridine dosing.
RNA sequencing of ﬂuorescence-activated cell sorting–
puriﬁed CRC CAFs was performed to identify a potential
therapeutic target in CAFs. To examine the prognostic significance of the stromal target, CRC patient RNA sequencing data
and tissue microarray were used. CRC organoids were injected
into the colons of knockout mice to assess the mechanism by
which the stromal gene contributes to colorectal tumorigenesis. RESULTS: Our lineage-tracing studies revealed that in
CRC, many ACTA2þ CAFs emerge through proliferation from
intestinal pericryptal leptin receptor (Lepr)þ cells. These Leprlineage CAFs, in turn, express melanoma cell adhesion molecule (MCAM), a CRC stroma-speciﬁc marker that we identiﬁed
with the use of RNA sequencing. High MCAM expression
induced by transforming growth factor b was inversely associated with patient survival in human CRC. In mice, stromal
Mcam knockout attenuated orthotopically injected colorectal
tumoroid growth and improved survival through decreased
tumor-associated macrophage recruitment. Mechanistically,
ﬁbroblast MCAM interacted with interleukin-1 receptor 1 to
augment nuclear factor kB–IL34/CCL8 signaling that promotes macrophage chemotaxis. CONCLUSIONS: In colorectal
carcinogenesis, pericryptal Lepr-lineage cells proliferate to
generate MCAMþ CAFs that shape the tumor-promoting immune microenvironment. Preventing the expansion/differentiation of Lepr-lineage CAFs or inhibiting MCAM activity could
be effective therapeutic approaches for CRC.
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microarray from human CRC samples. Finally, we uncover
the mechanism of stromal MCAM action in CRC with the
use of newly generated Mcam-null mice and mouse
colonoscopy.

Materials and Methods
Statistical Analysis
Comparison of 2 groups was performed using 2-tailed unpaired t tests or Mann-Whitney U tests. For multiple comparisons, we used analysis of variance or Kruskal-Wallis test. For
survival analyses, Kaplan-Meier survival estimation with a logrank (Mantel-Cox) test was performed. Statistical analyses were
conducted with the use of GraphPad Prism 8.00 or SPSS Statistics 25. P values of <0.05 were considered to be statistically
signiﬁcant.
For all other materials and methods, see the Supplementary
Materials.

Results
Desmoplasia Is Increased During Colorectal
Carcinogenesis in Humans and Mice
To explore whether desmoplasia is increased during
colorectal carcinogenesis and to identify a suitable mouse
model to investigate this, we performed immunohistochemistry for ACTA2, a well established marker for CAFs, in
human colorectal samples. The ratio of ACTA2þ ﬁbroblasts
in the total stromal cells increased from normal to lowgrade adenoma to high-grade adenoma, and ultimately
adenocarcinoma (Figure 1A and B). The elevated ACTA2
expression level during colorectal carcinogenesis was
corroborated by an analysis of expression microarray data
from human colorectal tissues (Supplementary Figure 1A).
Analyses of scRNA-seq data from human CRC tissues2 also
demonstrated that ACTA2 expression is increased in CAFs
compared with normal ﬁbroblasts, with the highest ACTA2
transcripts observed in pericytes among various CAF subpopulations (Figure 1C; Supplementary Figure 1B and C).
Next, we investigated the prognostic signiﬁcance of
ACTA2 expression in The Cancer Genome Atlas (TCGA) data.
High ACTA2 expression was inversely associated with
overall survival in patients with CRC (Figure 1D). High
ACTA2 expression, as well as high expression of FAP, an

=
Figure 1. ACTA2 expression is increased during colorectal carcinogenesis in humans and mice. (A, B) Immunohistochemistry
(IHC) for ACTA2 in human colorectal samples. (A) Representative pictures. (B) ACTA2 positivity in total stromal cells (visualized
by hematoxylin counterstaining). Three HPFs (400)/patient, 4–5 patients each. (C) Violin plots depict ACTA2 transcripts in
normal ﬁbroblasts (n ¼ 2053 cells) and CRC CAFs (n ¼ 1854 cells) assessed by means of single-cell RNA sequencing (scRNAseq) from human colorectal tissues. (D) Kaplan-Meier survival curves in The Cancer Genome Atlas (TCGA) data set. (E) Violin
plots showing ACTA2 expression level in 4 consensus molecular subtypes (CMSs). n ¼ 76, 220, 72, and 143 patients (CMS1–
4). (F) Scheme for the experimental course of azoxymethane (AOM)/dextran sulfate sodium (DSS)–induced colorectal carcinogenesis. (G) Representative endoscopic images of the normal colon mucosa and AOM/DSS tumors. T, tumor. (H, I)
Immunohistochemistry for ACTA2 in the normal mucosa and AOM/DSS tumors. (H) Representative pictures. (I) ACTA2 positivity in total stromal cells. 3 HPFs/mouse, 3 mice each. One-way analysis of variance followed by Tukey’s post hoc multiple
comparison test (B), Wilcoxon rank-sum test (C), log-rank test (D), Kruskal-Wallis test followed by Dunn’s multiple comparisons test (E), and 2-tailed unpaired Student t test (I): ****P < 0.0001; *P ¼ 0.0451. Scale bars, 50 mm. Box plots have whiskers
of maximum and minimum values; the boxes represent interquartile range and median. In violin plots, solid and dotted black
lines denote median and quartiles, respectively. ACTA2, a-smooth muscle actin; AOM, azoxymethane; CAF, cancerassociated ﬁbroblast ; CRC, colorectal cancer; DSS, dextran sulfate sodium; HPF, high-power ﬁeld.
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marrow in a mouse model of gastric cancer (ie, recruitment).8 Human studies have also suggested that bone
marrow contribution can be detected in CAFs in several
neoplasias, including colorectal.9 Others, however, have
suggested that local precursors were a predominant
contributor to ACTA2þ CAFs.10 Thus, the origin of CAFs
remains uncertain. In contrast to ﬁbrosis in organs such as
the liver, kidney, and skin, in which the origins of myoﬁbroblasts have been extensively investigated,11 to our
knowledge, no previous CAF studies have comprehensively
performed lineage-tracing experiments to track the
aforementioned 4 possible CAF sources.
Leptin receptor (Lepr) is a well established marker for
perivascular mesenchymal cells, which support bone
marrow hematopoietic stem cell (HSC) maintenance.12
Previous fate-mapping studies have demonstrated that
Lepr-expressing cells give rise to bone and adipocytes
formed in the adult normal bone marrow13 as well as
myoﬁbroblasts in primary myeloﬁbrosis.14 However, the
signiﬁcance of Lepr-lineage cells in the development of CAFs
is unknown.
Similar to Lepr, melanoma cell adhesion molecule
(MCAM; also known as CD146 and MUC18) is highly
expressed by perivascular stromal cells in the bone marrow
and has been suggested to be important in the HSC niche.15
MCAM is also expressed by endothelial cells, melanoma
cells, pericytes, and CAFs.16,17 MCAM expressed in endothelial and melanoma cells contributes to cancer progression by promoting cancer cell growth, angiogenesis, and
metastasis.17,18 Recently, scRNA-seq analyses have revealed
that MCAM deﬁnes a subset of pericyte-like CAFs that
secrete tumor-promoting immunomodulatory cytokines in
human cholangiocarcinoma and breast cancer.19,20 The
biological role of MCAMþ CAFs, however, has been poorly
deﬁned in CRC.
This study, for the ﬁrst time, comprehensively addresses the cellular origins, dynamics, and consequences of
speciﬁc CAFs in CRC. Using lineage tracing, we identify
intestinal pericryptal Lepr-lineage cells as a major source
of proliferating CAFs in a mouse model of CRC. Next, by
combining ﬂuorescence-activated cell sorting (FACS), RNAseq, and immunohistochemistry, we show these CAFs express MCAM. We investigate the clinical signiﬁcance of
MCAM expression with the use of RNA-seq data and tissue
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activated ﬁbroblast marker,1 was consistently associated
with poor prognosis across multiple expression datasets
from CRC patients (Supplementary Figure 2). The highest
ACTA2 expression was observed in the poor-prognosis
stroma-rich molecular subtype of CRC (consensus molecular subtype [CMS] 4)21 (Figure 1E).
We then sought to explore whether ACTA2þ ﬁbroblasts
are similarly increased in mouse models of CRC. To this end,
we performed ACTA2 immunohistochemistry with the use
of tumors from the azoxymethane (AOM)/dextran sulfate
sodium (DSS) (Figure 1F and G) and ApcMin/þ mouse
models. In line with a previous study,22 ACTA2 expression
was signiﬁcantly elevated in the stroma of AOM/DSS tumors
compared with the adjacent normal mucosa (Figure 1H and
I). Similarly, small intestinal tumors from ApcMin/þ mice
showed an increase in stromal ACTA2 expression compared
with the adjacent normal tissue, but to a lesser extent than
the AOM/DSS mouse model (Supplementary Figure 3).
Taken together, these data suggest that ACTA2þ ﬁbroblast
number increases throughout colorectal carcinogenesis in
humans, and this is recapitulated in the AOM/DSS mouse
model of CRC.

A Subpopulation of CRC CAFs Arises Through
Proliferation in Humans and Mice
We next addressed the question of whether CAFs
emerge through cell division or simply increase ACTA2
expression in existing cells. Co-staining for ACTA2 and Ki67
with the use of human colorectal samples revealed that the
percentage of ACTA2 and Ki67 double-positive cells (ie,
proliferating ACTA2þ CAFs) was increased in high-grade
adenoma and adenocarcinoma compared with normal
colorectal mucosa, with about 10% of ACTA2þ CAFs marked
by Ki67 in adenocarcinoma (Figure 2A and B). Analysis of
scRNA-seq data from human CRC and normal mucosa2
conﬁrmed that a subcluster of ACTA2þ CAFs expressed
MKI67, and this co-expressing population was not found in
ﬁbroblasts from the normal mucosa (Supplementary
Figure 4). These data suggest that human CRC CAFs undergo mitosis during malignant progression.
Ki67 only temporarily marks actively cycling cells, so
our analysis of proliferation of human CRC CAFs may underestimate CAFs that divided at an earlier time point. To
capture the entire population of CAFs that underwent
proliferation during carcinogenesis, we took advantage of
continuous 5-bromodeoxyuridine (BrdU) labeling in the
AOM/DSS mouse model. After the last course of DSS/water

=
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treatment (5-day DSS treatment followed by a 16-day recovery period with normal drinking water), BrdU dosing
commenced at the onset of observable tumors (Figure 2C).
The ratio of ACTA2þ ﬁbroblasts that incorporated BrdU was
signiﬁcantly elevated in AOM/DSS tumors compared with
the adjacent nonneoplastic colon, with approximately 75%
of ACTA2þ ﬁbroblasts in AOM/DSS tumors marked by BrdU
(Figure 2D and E; Supplementary Figure 5). Colonoscopic
and microscopic evaluation of AOM/DSS tumors conﬁrmed
the absence of excavated ulcers or severe inﬂammation at
the time point when BrdU labeling started (Figure 2C;
Supplementary Figure 6). These data indicate that ACTA2þ
ﬁbroblasts have divided during AOM/DSS tumorigenesis,
after DSS-induced acute colitis subsided. Contrasting with
the BrdU incorporation ratio, the ratio of actively proliferating ﬁbroblasts (Ki67þACTA2þ ﬁbroblasts) in the total
pool of ACTA2þ ﬁbroblasts was only about 1.5% in AOM/
DSS tumors and was not signiﬁcantly different from the
ratio of proliferating ﬁbroblasts in the normal mouse
colorectal mucosa (Figure 2D and E). Collectively, our data
suggest that, in AOM/DSS tumors, the majority of ACTA2þ
ﬁbroblasts at humane end point were in quiescent G0 phase
as evaluated by Ki67 negativity, but approximately threefourths of the ﬁbroblasts had undergone cell division and
incorporated BrdU during colitis-associated tumorigenesis
after the last DSS/recovery cycle.

Lepr-Lineage Stromal Cells Are a Major
Contributor to the Proliferating Fibroblasts in
AOM/DSS CRC
We next sought to establish the cellular origin of the
proliferating ﬁbroblasts in AOM/DSS tumors by using a
lineage-tracing strategy. We selected transgenic mouse lines
that 1) identiﬁed putative colorectal mesenchymal stemprogenitor cells (Lepr-Cre; Rosa26-LSL-tdtomato,12 Grem1CreERT2; Rosa26-LSL-ZsGreen23 and Islr-CreERT2; Rosa26LSL-tdtomato3), 2) labeled epithelium (Krt19-Cre; Rosa26mt/mG), or 3) marked bone marrow–derived cells through a
combination of bone marrow from Acta2–red ﬂuorescent
protein (RFP) mouse transplanted into non-RFP recipients
(Figure 3). These fate-mapping experiments were coupled
with BrdU labeling beginning at the onset of observable tumors
after the last DSS/recovery cycle (Figure 2C). Tamoxifen was
administered to the inducible Cre lines at postnatal day 6.
Immunoﬂuorescence for EPCAM, a pan-epithelial cell
marker, showed that all Lepr-, Grem1-, and Islr-lineage cells
were observed only within the EPCAM stroma, validating

Figure 2. A subset of ACTA2þ CAFs proliferate during colorectal carcinogenesis in humans and mice. (A, B) Coimmunoﬂuorescence for ACTA2 and Ki67 in human colorectal samples. (A) Representative pictures. Yellow arrowheads
denote proliferating CAFs (ACTA2þKi67þ cells). (B) Ki67 positivity in total ACTA2þ cells. Three HPFs (400)/patient, 4–5
patients each. (C) Scheme for the experimental course of AOM/DSS-induced colon carcinogenesis and BrdU administration.
After the end of the last DSS/water cycle, continuous BrdU administration was commenced once a visible tumor was observed
via mouse colonoscopy. T, tumor. (D, E) Co-immunoﬂuorescence for ACTA2, BrdU, and Ki67 in the normal colon mucosa and
AOM/DSS tumors. (D) Representative images. Blue and yellow arrowheads denote ACTA2þBrdU and ACTA2þBrdUþ cells,
respectively. (E) BrdU positivity (left) and Ki67 positivity (right) in total ACTA2þ cells. 3 HPFs/mouse, 3 mice each. KruskalWallis test followed by Dunn’s multiple comparisons test (B) and 2-tailed unpaired Student t test (E): ****P < 0.0001; **P ¼
0.0077; ns, P ¼ 0.0857. Scale bars, 50 mm. BrdU, 5-bromodeoxyuridine; other abbreviations as in Figure 1.
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their mesenchymal identity (Figure 3A). In AOM/DSS tumors,
approximately one-half of ACTA2þ ﬁbroblasts and 75% of
proliferating BrdUþACTA2þ ﬁbroblasts were Lepr-lineagepositive, with a smaller proportion of ACTA2þ ﬁbroblasts
derived from the Grem1-lineage and Islr-lineage (Figure 3A
and C–E). Lepr-lineage cells represented about 47.1% and
17.4% of the total PDGFRAþ ﬁbroblasts in the AOM/DSS
tumors and normal colons, respectively (Supplementary
Figure 7). Together, these results suggest that Lepr-lineage
stromal cells are a major source of proliferating ACTA2þ ﬁbroblasts during AOM/DSS carcinogenesis.

Lepr-Lineage Cells Contribute to ACTA2þ
Proliferating CAFs in a CRC Organoid
Transplantation Model
We next asked whether Lepr-lineage cells also give rise to
proliferating ACTA2þ CAFs in a distinct model of CRC. To this
end, we colonoscopically injected ApcD/D, KrasG12D/D, Trp53D/D
mouse CRC organoids (hereafter termed AKP tumoroids) into
the colons of Lepr-Cre; Rosa26-LSL-tdtomato mice
(Supplementary Figures 8 and 9A). Continuous BrdU dosing
commenced 1 day after tumoroid transplantation. In this
model, approximately 72% of ACTA2þ CAFs underwent proliferation as assessed by BrdU positivity (Supplementary
Figure 9B and C). Similarly to our ﬁndings with the AOM/
DSS model, Lepr-lineage cells were a major contributor to
BrdUþACTA2þ CAFs in this model, with 53% of the proliferating CAFs derived from Lepr lineage (Supplementary
Figure 9B–E). Our Lepr-lineage tracing data from colitisassociated and sporadic CRC models suggest that the majority of proliferating ACTA2þ CAFs in CRC originate from Leprlineage cells.

Neither Epithelium nor Bone Marrow Recruitment
Contributed to ACTA2þ CAFs in the AOM/DSS
Mouse Model of CRC
We explored whether colonic epithelial cells could undergo epithelial-mesenchymal transition into colorectal
CAFs. For this purpose, we used constitutive Krt19-Cre;
Rosa26-mt/mG mice to track the fate of Krt19-lineage
colonic epithelial cells. All colonic cells with epithelial
morphology were marked after reporter recombination by

=

Colorectal Cancer–Associated Fibroblasts

897

Cre recombinase driven by the Krt19 promoter (Figure 3B).
However, no Krt19-lineage cells were positive for ACTA2 in
either normal colon or AOM/DSS tumors (Figure 3B and D).
This suggests that, at least in this mouse model of CRC, the
epithelium is not a source of ACTA2þ CAFs.
Next, to assess the contribution of bone marrow–derived
cells to the AOM/DSS tumor stroma, we performed bone
marrow transplantation experiments with the use of an
Acta2-RFP reporter mouse as a donor. Initially, we validated
that, in Acta2-RFP mice that did not undergo bone marrow
transplantation, RFP was expressed by ﬁbroblastic cells in
AOM/DSS tumors, conﬁrming that the Acta2 promoter is
active in this CRC mouse model (Supplementary Figure 10).
To perform bone marrow transplantation from Acta2-RFP
mice, wild-type recipient mice were subjected to total body
irradiation and transplanted with whole bone marrow cells
from Acta2-RFP donor mice. Then, the mice were treated
with AOM/DSS to induce colorectal tumors (Supplementary
Figure 11A). Quantitative polymerase chain reaction for RFP
with the use of genomic DNA isolated from the bone
marrow of the recipient mice conﬁrmed engraftment of
RFPþ cells in the recipient bone marrow (Supplementary
Figure 11B). Transplanted Acta2-RFPþ cells were also
observed in the small intestine of the wild-type recipients,
further validating the engraftment (Supplementary
Figure 11C). However, no bone marrow–transplanted
RFPþ cells were observed in AOM/DSS tumors in wildtype recipient mice (Figure 3B and D). This indicates that,
at least in this experimental CRC model, CAFs did not arise
via recruitment from the bone marrow, but only from local
precursors.
Collectively, our data with 5 distinct genetically engineered mouse models suggest that tissue-resident Leprlineage stromal cells are a key contributor to the ACTA2þ
CAFs in AOM/DSS tumors.

Lepr-Lineage Intestinal Stromal Cells Undergo
Proliferation and Differentiation Into ACTA2þ
CAFs During AOM/DSS Carcinogenesis
We next sought to characterize Lepr-lineage cells in the
normal colon and AOM/DSS tumors. In the normal colonic
mucosa, pericryptal Lepr-lineage cells were preferentially
located near the base of the crypts (Figure 3F and G). Lepr-

Figure 3. Proliferating ACTA2þ ﬁbroblasts in AOM/DSS tumors derive predominantly from Lepr-lineage cells. (A) Immunoﬂuorescence for ACTA2 and EPCAM (a pan-epithelial cell marker) in the normal colon mucosa and AOM/DSS tumors with the
use of fate-mapping mouse models. Yellow arrowheads denote lineage-markerþACTA2þ cells. See (D) for quantiﬁcation. R26,
Rosa26-loxP-stop-loxP; BM, bone marrow; BMT, bone marrow transplantation; GFP, green ﬂuorescent protein; RFP, red
ﬂuorescent protein; TAM, tamoxifen. (B) Immunoﬂuorescence for ACTA2 in the normal mucosa and AOM/DSS tumors in
Krt19-Cre mice (left). Immunoﬂuorescence for ACTA2 and EPCAM in the normal mucosa and AOM/DSS tumor, in a wild-type
recipient mouse transplanted with bone marrow cells from an Acta2-RFP mouse (right). (C) Immunoﬂuorescence for ACTA2
and BrdU in AOM/DSS tumors in the BrdU-treated fate-mapping mouse models. Yellow arrowheads denote proliferating CAFs
that were derived from each cellular lineage (lineage-markerþACTA2þBrdUþ cells). (D) The ratios of lineage-markerþ cells in
total ACTA2þ cells. 4 HPFs/mouse. n ¼ 3 mice (Lepr-Cre, Grem1-CreERT2, Islr-CreERT2, Acta2-RFP) and n ¼ 2 mice (Krt19Cre). (E) The ratios of lineage markerþ cells in total proliferating CAFs. 4 HPFs/mouse. 3 mice each. (F, G) Cellular positions of
Lepr-lineage stromal cells in the normal adult mouse colon. (F) Representative pictures. White arrowheads denote Lepr-lineage
tdtomatoþ cells. (G) Violin plots showing the positions of pericryptal Lepr-lineage stromal cells relative to the adjacent epithelial
position. n ¼ 81 Lepr-lineage cells from 3 mice. Scale bars, 50 mm. Two-tailed unpaired t test with Welch’s correction (D) and
Kruskal-Wallis test followed by Dunn’s multiple comparisons test (E): ****P < 0.0001; **P ¼ 0.0030 (D); **P ¼ 0.0043 (E). Lepr,
leptin receptor; other abbreviations as in Figures 1 and 2.
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lineage stromal cells in AOM/DSS tumors exhibited higher
ACTA2 positivity than Lepr-lineage stromal cells in the
normal mucosa, indicating that Lepr-lineage cells underwent
phenotypic conversion into ACTA2þ CAFs during carcinogenesis (Supplementary Figure 12A and B). BrdU labeling in
AOM/DSS-treated mice revealed that Lepr-lineage cells
showed higher proliferation in AOM/DSS tumors compared
with the adjacent normal mucosa (Supplementary
Figure 12C and D). Single-molecule ﬂuorescent RNA in situ
hybridization for Lepr revealed that active expression of
Lepr in Lepr-lineage cells was reduced in the AOM/DSS tumor compared with the normal colon (Supplementary
Figure 12E and F). Together, these ﬁndings indicate that
intestinal Lepr-lineage stromal cells undergo expansion and
differentiation to ACTA2þ myoﬁbroblasts at the expense of
Lepr expression during AOM/DSS colorectal carcinogenesis.

Identiﬁcation of MCAM as a CRC StromaSpeciﬁc Marker That Deﬁnes a Subset of
Lepr-Lineage Proliferating CAFs.
Lower Lepr expression in the CRC mesenchyme could
potentially make it challenging to therapeutically target
Lepr-lineage CAFs based on active Lepr expression in
established cancers. Therefore, we next aimed to identify a
stromal factor that is actively expressed in the CRC
mesenchyme as a potential therapeutic stromal target to
treat CRC.
As a strategy to identify the most biologically relevant
stromal targets, we were inspired by the parallels between
cancer and developmental biology.24,25 For example, factors
involved in ﬁbroblast activation (eg, TGF-b) and inﬂammation (eg, nuclear factor (NF) kB) play crucial roles in both
carcinogenesis and organ development.1,25,26 Therefore, we
decided to triangulate the ﬁbroblastic factors that were
signiﬁcantly up-regulated in both tumorigenesis and development compared to adult colonic ﬁbroblasts.
We ﬁrst sorted ﬁbroblasts using a negative selection
strategy. Fibroblasts were selected based on their lack of
expression of blood cell markers (CD45 and Ter119), an
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endothelial marker (CD31), and an epithelial marker
(EPCAM) from AOM/DSS tumors, developmental colon
(postnatal day 14), and normal adult colon (Figure 4A).
Fibroblast markers such as Grem1, Acta2, and Fap were
highly expressed in the FACS-sorted mesenchymal cells
(CD45, Ter119, CD31, EPCAM), validating their
enrichment for ﬁbroblasts (Supplementary Figure 13).
RNA-seq from the FACS-puriﬁed ﬁbroblasts revealed that
342 genes were differentially up-regulated in both the
AOM/DSS tumors and the early postnatal colons compared
with the normal adult colon ﬁbroblasts (Figure 4B, step 1).
Next, we analyzed the prognostic signiﬁcance of these 342
genes by performing survival analysis with the use of TCGA
data, resulting in the selection of 46 genes that were
associated with human CRC survival (Figure 4B, step 2;
Supplementary Table 1). Next, to focus on stroma-speciﬁc
targets, using our RNA-seq data from normal adult colon
and AOM/DSS tumors, we selected 18 stroma-speciﬁc
genes that were up-regulated in ﬁbroblasts compared
with epithelial cells (Figure 4B, step 3; Supplementary
Table 1). Then, to examine for genes expressed at the
protein level in human CRC stroma, we interrogated human CRC immunohistochemistry data in the Human Protein Atlas database and selected 6 proteins that were
highly expressed in the CRC stroma (Figure 4B, step 4;
Supplementary Figure 14). Finally, our immunohistochemistry data for candidate genes showed that MCAM was
the only candidate that was consistently up-regulated in
the stroma of AOM/DSS tumors and the developmental
colon compared with the normal adult colon (Figure 4C
and D; Supplementary Figure 15).
Next, we explored the stromal MCAM expression in human and mouse colorectal tissues. Analyses of scRNA-seq
from human CRC tissues2 and ulcerative colitis samples
revealed that the high MCAM expression was observed in
pericytes compared with other cell subpopulations such as
endothelial cells, epithelial cells, and immune cells
(Supplementary Figure 16A and B). In AOM/DSS tumors, coimmunoﬂuorescence for CD31, ACTA2, CD45, and EPCAM
showed that approximately 45% of MCAMþ cells expressed

=
Figure 4. Identiﬁcation of MCAM as a CRC mesenchyme–speciﬁc marker that represents a subset of Lepr-lineage proliferating
cells. (A) Experimental schematic for isolating colonic ﬁbroblasts from the normal adult colon, AOM/DSS tumors, and postnatal
day 14 colon. Gating strategy to isolate CD45Ter119CD31EPCAM ﬁbroblasts by ﬂuorescence-activated cell-sorting
(FACS) is shown for 1 mouse adult normal colon. n ¼ 4 mice each. (B) Strategy to identify a colonic stromal gene up-regulated
in development and carcinogenesis, which is associated with human CRC survival. (1) Venn diagram showing 342 genes upregulated in AOM/DSS tumors and postnatal day 14 colon compared with normal adult colon ﬁbroblasts. (2) Survival analysis
using The Cancer Genome Atlas (TCGA) data set. (3) Using our RNA sequencing data, genes up-regulated in
EPCAMCD31CD45Ter119 ﬁbroblasts compared with EPCAMþ epithelial cells, in both normal adult colon and AOM/DSS
tumors, were selected. Mean ± SEM. (4) The Human Protein Atlas data were used to select genes whose protein expression
was restricted to the CRC stroma. Mcam is highlighted in red. (C, D) Immunohistochemistry (IHC) for MCAM. (C) Representative images. Blue, red, and green arrowheads denote MCAM expression in the normal adult colon, AOM/DSS tumor, and
postnatal day 14 colon, respectively. (D) The ratios of MCAMþ cells in total stromal cells (visualized by means of hematoxylin
counterstaining). 3 HPFs/mouse, 3 mice each. (E) Co-Immunoﬂuorescence for MCAM and ACTA2 with the use of AOM/DSS
tumors from Lepr-Cre; Rosa26-tdtomato mice. Yellow arrowheads denote Lepr-lineage MCAMþ ACTA2þ CAFs. See
Supplementary Figure 17C and D for quantiﬁcation and separate channel images. (F, G) Co-immunoﬂuorescence for MCAM
and BrdU. (F) Representative images. Yellow arrowheads denote proliferating MCAMþ cells. (G) The ratio of MCAMþBrdUþ
cells in total MCAMþ cells. 3 HPFs/mouse, 2–3 mice each. Scale bars, 50 mm. Log-rank test (B(2)), 1-way analysis of variance
followed by Tukey’s post hoc multiple comparison test (B(3) and D), and 2-tailed unpaired Student t test (G): ****P < 0.0001.
MCAM, melanoma cell adhesion molecule; other abbreviations as in Figures 1–3.
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a pericyte/CAF marker, ACTA2 (Supplementary Figure 16C
and D).
To characterize the cellular sources of MCAMþ CAFs in
CRC, we performed immunoﬂuorescence for MCAM in the 3
mesenchymal fate-mapping mouse models (Lepr-Cre,
Grem1-CreERT2, and Islr-CreERT2 mice). Our data revealed
that about 80% of MCAMþACTA2þ CAFs were derived from
the Lepr lineage in AOM/DSS tumors (Figure 4E;
Supplementary Figure 17). We also co-stained MCAM and
BrdU in AOM/DSS-treated mice that were administered
BrdU during carcinogenesis. In keeping with previous
scRNA-seq data showing that Mcam was highly expressed
by a proliferative subpopulation of CAFs,5 more than half of
the MCAMþ cells were positive for BrdU, indicating that the
majority of MCAMþ cells arose through proliferation
(Figure 4F and G). Collectively, these data indicate that
MCAM identiﬁes Lepr-lineage proliferating CAFs in AOM/
DSS tumors.

Colorectal Cancer–Associated Fibroblasts

901

human colorectal CAFs,2 as well as bulk CRC tissue analysis
of TCGA and expression microarray data, showed positive
correlations between MCAM and ACTA2 expression
(Figure 5E; Supplementary Figure 19).
Next, to conﬁrm the clinical association between MCAM
expression and survival, we performed MCAM immunohistochemistry with the use of tissue microarrays from our
own independent cohort of 101 CRC patients. Consistent
with a previous paper,27 high MCAM expression was an
independent prognostic factor for poor overall survival in
CRC patients (Figure 5F and G; Supplementary Tables 2 and
3). Moreover, analyses of 4 independent CRC data sets
conﬁrmed that high MCAM expression was inversely associated with survival (Supplementary Figure 20). Taken
together, these data indicate that high MCAM expression
driven, at least in part, by TGF-b predicts poor prognosis in
human CRC.

Increased MCAM Expression Is Associated With
CMS4 and Predicts Poor Survival in Patients With
CRC

Genetic Deletion of Stromal Mcam Inhibits
Colorectal Tumorigenicity and Improves Survival
via Decreased NF-kB–IL34/CCL8–Mediated
Macrophage Recruitment

We investigated the clinical signiﬁcance of MCAM
expression in CRC patients. Consistent with the observed upregulation of MCAM during mouse colorectal tumorigenesis,
MCAM expression was increased in the human adenomacarcinoma sequence (Figure 5A and B). Analyses of expression microarray data from human colorectal tissues also
showed that MCAM transcripts were elevated during colorectal carcinogenesis (Supplementary Figure 18A and B).
Furthermore, scRNA-seq data from human colorectal tissues2
demonstrated that, among ﬁbroblast subpopulations, MCAM
expression was increased in pericytes during carcinogenesis
(Supplementary Figure 18C and D).
Analyses of the TCGA data set showed that the highest
expression of MCAM was observed in poor-prognosis
immunosuppressive CMS4 tumors (Figure 5C). Given that
TGF-b signaling activation is a deﬁning characteristic of
CMS4 CRC,21 we reasoned that TGF-b might up-regulate
MCAM expression. In keeping with our hypothesis, stimulation of a mouse colonic ﬁbroblast cell line, YH2 cells, with
recombinant TGF-b1 enhanced Mcam transcript levels and a
TGF-b target gene, Acta2 (Figure 5D). This was rescued by
co-treatment with galunisertib, a speciﬁc inhibitor for TGF-b
receptor 1. Consistent herewith, scRNA-seq analysis of

Finally, to delineate the mechanism by which MCAM
contributes to CRC progression, we generated Mcamknockout mice by means of CRISPR/Cas9-mediated genome
engineering (Supplementary Figure 21A) and colonoscopically injected luciferase-expressing AKP tumoroids into the
colons of Mcam-knockout and wild-type mice (Figure 6A). In
this mouse model, more than half of MCAMþ cells were
ACTA2þ CAFs (Supplementary Figure 21B and C). Consistent with our earlier MCAM expression and survival analyses from human CRC, Mcam-knockout mice showed
prolonged survival after tumoroid injection (Figure 6B).
Mcam-knockout mice also demonstrated reduced tumoroidderived luciferase signals according to in vivo imaging system, decreased tumor volumes, and colonoscopic tumor
scores (Figure 6C–F; Supplementary Figure 22A and B). In
keeping with this, tumors from Mcam-knockout mice
showed reduced histologic tumor area and Ki67 labeling
(Supplementary Figure 22C–F).
Immunohistochemistry for various immune cell markers
revealed that inﬁltration of CD68þ macrophages and CD11bþ
myeloid-derived cells was decreased in tumors from Mcamknockout mice (Figure 6G and H). This was accompanied by
decreased FOXP3þ regulatory T cells and increased CD8þ

=

Figure 5. High stromal MCAM expression driven, in part, by transforming growth factor (TGF) b is associated with poor survival
in patients with CRC. (A, B) Immunohistochemistry (IHC) for MCAM in human colorectal samples. (A) Representative pictures.
(B) MCAM positivity in total stromal cells (visualized by hematoxylin counterstaining). 3 HPFs (400)/patient, 4–5 patients
each. (C) Violin plots showing MCAM expression levels in 4 CMSs. n ¼ 76, 220, 72, and 143 patients (CMS1–4). TCGA, The
Cancer Genome Atlas. (D) A mouse colonic ﬁbroblast cell line, YH2, was incubated with vehicle, recombinant TGF-b1, or
recombinant TGF-b1 þ TGF-b1 receptor inhibitor (galunisertib) for 24 hours, followed by quantitative reverse-transcription
polymerase chain reaction. Mean ± SEM. n ¼ 3. DMSO, dimethylsulfoxide. (E) Single-cell RNA sequencing data show that
MCAM transcript levels are positively correlated with ACTA2 expression in colorectal CAFs. n ¼ 1854 CAFs. Solid line, linear
regression. (F, G) MCAM IHC in a CRC tissue microarray (F) Representative images and scoring system. (G) Kaplan-Meier
survival curves. Scale bars, 50 mm. Kruskal-Wallis test followed by Dunn’s multiple comparisons test (B and C), 1-way
analysis of variance followed by Tukey’s post hoc multiple comparison test (D), Spearman correlation (E), and log-rank test
(G): ****P < 0.0001; *P ¼ 0.0124. Abbreviations as in Figures 1 and 4.
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rescued by co-treatment with IKK16, a selective inhibitor
for IkB kinase. We reasoned that MCAM might act as a coreceptor for IL1b receptor, IL1R1, to potentiate IL1b–NFkB–IL34/CCL8 signaling. To this end, we lentivirally transduced YH2 cells with MCAM-hemagglutinin (HA) epitope tag
or, as a control, mScarlet-HA, and performed immunoprecipitation with an anti-HA antibody. The coimmunoprecipitation revealed that MCAM interacted with
IL1R1 (Figure 6M). Reciprocal co-immunoprecipitation of
MYC-tagged IL1R1 with the use of an anti-MYC antibody
veriﬁed the interaction of IL1R1 with MCAM
(Supplementary Figure 27). In line with our in vitro data,
tumors from Mcam-knockout mice showed lower stromal
expression of Il34 and Ccl8 (Figure 6N and O), accompanied
by decreased NF-kB phosphorylation (Supplementary
Figure 28). In human CRC, TCGA and expression microarray data conﬁrmed that MCAM expression was positively
correlated with IL34 and CCL8, as well as CD68 and ITGAM
(CD11b) expression (Supplementary Figure 29). Collectively, our data indicate that MCAM alters the immune
microenvironment and accelerates CRC progression, in part,
through increased TAM recruitment mediated by IL1R1–NFkB–IL34/CCL8 signaling.

Discussion

In this study, we have shown that about 75% of ACTA2þ
CAFs in CRC were generated through proliferation, with the
remaining 25% acquired through new or preserved ACTA2
expression in existing ﬁbroblasts (ie, activation). Most
proliferating ACTA2þ CAFs were derived from intestinal
Lepr-lineage stromal cells. These Leprþ pericryptal ﬁbroblasts are also the chief origin of proliferating MCAMþ CAFs.
High stromal MCAM expression is associated with poor
clinical outcomes in patients with CRC. Furthermore,
transgenic knockout of Mcam in the colorectal tumor
microenvironment limits tumor growth and improves

=
Figure 6. Stromal MCAM promotes CRC progression via IL1R1-p65-IL34/CCL8 signaling–mediated macrophage recruitment.
(A) Experimental scheme showing orthotopic injection of ApcD/D, KrasG12D/D, Trp53D/D CRC organoids (AKP tumoroids) into
the colon. (B) Kaplan-Meier survival curves. (C, D) Luciferase signals from AKP tumoroids were assessed with the use of IVIS.
18 Mcam-WT and 16 Mcam-KO mice. (E, F) Macroscopic evaluation of colon tumors, harvested 3 weeks after tumoroid injection. (E) Representative pictures. Dotted lines indicate tumors. (F) Quantiﬁcation of tumor volumes. 2 injections/mouse, 8
Mcam-WT and 6 Mcam-KO mice. (G, H) Immunohistochemistry (IHC) for CD68 and CD11b. (G) Representative pictures. M,
macrophages as assessed by morphology. (H) DAB-positive areas. A.U., arbitrary units. (I) Venn diagram showing the overlap
of 41 macrophage/monocyte chemoattractant genes identiﬁed by means of Gene Ontologies and 462 genes up-regulated in
MCAMhigh CAFs compared with MCAMlow CAFs (scRNA-seq data from GSE132465). (J, K, L) Lentivirus-mediated overexpression of MCAM augments IL1b-p65-Il34/Ccl8 signaling in YH2 cells. MCAM-overexpressing or empty YH2 cells were
stimulated with recombinant IL1b, followed by WB (J, K) and quantitative reverse-transcription polymerase chain reaction. (L).
Mean ± SEM. n ¼ 3 each. p-p65, phosphorylated p65. (M) Immunoprecipitation (IP) for MCAM-hemagglutinin (HA) tag with an
anti-HA antibody, followed by WB. A green asterisk denotes the interaction of MCAM-HA with IL1R1. An anti-MYC antibody
was used to detect IL1R1 protein tagged with MYC. Blue and red dotted boxes indicate mScarlet-HA and MCAM-HA proteins,
respectively. (N, O) In situ hybridization (ISH) for Il34, Ccl8, and a negative control probe (bacterial DapB gene) (N) Representative pictures. Green dotted lines indicate borders between stromal (S) and epithelial (E) areas (visualized by means of
hematoxylin counterstaining). Red arrowheads denote Il34þ or Ccl8þ stromal cells. (O) DABþ areas in the tumor stroma. Scale
bars, 200 mm (A), 2 mm (E), 50 mm (G and N). All histopathologic analyses were performed with the use of mice killed 3 weeks
after tumoroid injection. 3 HPFs (400)/tumor, 1–2 tumors/mouse, 5 mice each group (H and O). Log-rank test (B), 2-tailed
unpaired t test with Welch’s correction (D), Mann-Whitney U test (F, H, and O), and 2-way analysis of variance followed by
Tukey’s post hoc multiple comparison test (K and L): ****P  0.0001; ***P  0.001; *P  0.05; ns, P > 0.05. AU, arbitrary units;
DAB, 3,30 -diaminobenzidine; KO, knockout; IVIS, in vivo imaging system; WB, Western blotting; WT, wild type; other abbreviations as in Figures 1 and 4.
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cytotoxic T cells in Mcam-knockout mice (Supplementary
Figure 23A and B). In our mouse model, we did not observe
alterations in CD31þ vasculature density or ACTA2þ CAF area
by Mcam knockout (Supplementary Figure 23C–F). Normal
adult colons from Mcam-knockout mice did not show altered
Ki67 labeling or crypt density or length (Supplementary
Figure 24). This suggests that, in Mcam-knockout mice,
there are no pre-existing changes in normal colon morphogenesis that lead to the altered tumor size.
Consistent with our mouse immunophenotyping data,
gene set enrichment analysis with the use of TCGA data
revealed positive enrichment of macrophage/monocyte
chemotaxis genes in MCAMhigh cancers compared with
MCAMlow tumors (Supplementary Figure 25). We hypothesized that MCAMþ CAFs might promote tumor-associated
macrophage (TAM) recruitment, contributing to the immunosuppressive tumor microenvironment. To identify
macrophage/monocyte chemoattractants secreted by
MCAMþ CAFs, we ﬁrst performed differential gene expression analysis with the use of scRNA-seq data from human
CRC2 and found that 462 genes were up-regulated in
MCAMhigh CAFs compared with MCAMlow CAFs (Figure 6I).
Next, using gene ontologies, we examined transcripts
encoding cytokines and chemokines involved in macrophage/monocyte chemotaxis. This analysis identiﬁed IL34
and CCL8 as genes with roles in TAM recruitment that are
up-regulated in MCAMhigh CAFs.
Next, to assess whether MCAM could promote IL34 and
CCL8 expression, we overexpressed MCAM in YH2 cells by
means of lentiviral transduction and stimulated MCAM-YH2
cells with recombinant interleukin (IL) 1b, which is known
to induce IL34 and CCL8 expression in ﬁbroblasts.28,29 As
expected, IL1b–treated MCAM-YH2 cells showed decreased
IkBa expression, increased phosphorylation of NF-kB (p65),
and enhanced luciferase signals from NF-kB–responsive elements, leading to up-regulation of Il34 and Ccl8 (Figure 6JL; Supplementary Figure 26). These alterations were
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survival by modifying TAM recruitment and immune landscapes. These data suggest that MCAM, a prominent cell
surface protein, could prove to be a valuable novel stromal
target in the prevention and treatment of CRC.
Several studies have indicated that recruitment from the
bone marrow could contribute to CAFs in mouse models of
cancers such as gastric and breast cancer.8,30 In contrast, one
paper demonstrated that no Acta2-RFPþ CAFs were detected
in small intestinal tumors developed in a parabiosis study of
an ApcMin/þ with an Acta2-RFP mouse.10 In agreement with
this, we found that no ACTA2þ CAFs were derived from the
bone marrow in an AOM/DSS model of CRC. To our knowledge, our study is the ﬁrst to examine bone marrow contribution to CAFs in tumors in the mouse colon. Human studies
using secondary tumors (including colorectal neoplasias)
developed after sex-mismatched bone marrow transplantation also indicated that bone marrow–derived cells are
not a major contributor to ACTA2þ CAFs.9,31 It is plausible,
and indeed likely, that the origins and contributions of CAFs
are context dependent, depending on cancer stage, cancer
genetics, and organ-speciﬁc microenvironment.
Intestinal normal and neoplastic epithelium develop
from stem-progenitor cell hierarchies.32 Analogously to this,
we have previously shown that Grem1þ intestinal reticular
stromal cells identify connective tissue stem cells in the
normal small intestine.23 Here, our data indicate that the
majority of CRC CAFs, however, arise not from Grem1þ cells,
but from intestinal Lepr-lineage pericryptal cells. Interestingly, a recent paper found that Gli1þ pancreatic stellate
cells could contribute to approximately half of ACTA2þ CAFs
in a mouse model of pancreatic cancer.33 Further research is
required to determine the hierarchic or overlapping relationship between Lepr-lineage and Gli1-lineage CAFs in
different tissues in health and neoplasia.
One limitation of the present study is that we were not
able to ascertain whether Lepr-lineage CAFs display cellular
plasticity during cancer development, as has been shown to
occur in cancer stem cells,32 or whether they undergo an
irreversible “lineage-restricted” differentiation. Given that
CAFs are considered to exhibit tumor stage–dependent
phenotypes,1,34 it is conceivable that Lepr-lineage CAFs
could adapt to dynamic phenotypic shifts during colorectal
carcinogenesis and co-evolve with epithelial genetic events.
Another limitation of this study is that we have not
determined whether MCAM expression is induced by TGFb in Lepr-lineage ﬁbroblasts during colorectal tumorigenesis, despite showing that TGF-b up-regulates Mcam
expression in colonic ﬁbroblasts in vitro. TGF-b signaling
plays a key role in differentiation of Tcf21þ hepatic stellate cells to ACTA2þ CAFs, thereby promoting liver tumor
progression.35 Further research is warranted to investigate whether conditional knockout of a TGF-b receptor in
Lepr-lineage cells could suppress MCAM expression and
thus attenuate cancer progression in a mouse model of
CRC.
This work also demonstrated that MCAM is an attractive
therapeutic target that modiﬁes the immunosuppressive
milieu through augmenting NF-kB signaling, key signaling
that deﬁnes inﬂammatory phenotypes in CAFs.6,36,37
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Excitingly, MCAM-neutralizing antibodies show promising
results in restraining cancer progression in preclinical
models, including an AOM/DSS model.17,18 Future research
should focus on investigating whether co-treatment of the
MCAM-neutralizing antibody and an immune checkpoint
inhibitor could unleash a cytotoxic immune response
against immunologically “cold” cancers that are resistant to
immunotherapies.
In conclusion, our data show that Lepr-lineage intestinal
stromal cells, resident at the pericryptal base in the normal
colon, proliferate in colorectal carcinogenesis to generate
MCAMþ CAFs. We also show that MCAM is an important
factor in sculpting the detrimental immune microenvironment responsible for driving colorectal carcinogenesis and
the associated poor patient outcome. In the future, approaches to reduce the expansion of Leprþ pericryptal cells,
prevent their differentiation into MCAMþ CAFs, and inhibit
the activity of MCAM-mediated NF-kB signaling axis in
mature CAFs may all have considerable clinical value in the
treatment of colorectal cancer.

Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/j.
gastro.2021.11.037.
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